ClinicalTrials.gg
CompletedNCT02631941Updated Feb 23, 2022Results posted

Clinical Study to Evaluate Z7200 Pharmacokinetics Profile

A Phase 1 interventional study of Z7200 without oral activated charcoal and Symbicort Turbohaler without oral activated charcoal in Asthma, sponsored by Zambon SpA. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-23.

Sponsored by Zambon SpA · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
67th of 108
91 · median 124
Started
2016
with 5 others
Phase 1
10 of 110
none open now
Registered
83rd of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is the 67th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2016, is one of 10 in phase 1, and was the 83rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

Brief Summary:

The primary objective was:

  • to assess the bioequivalence of a single dose (two inhalations) of the test product compared to the reference product, with and without charcoal blockade.

The secondary objectives were:

  • to assess the pharmacokinetic profile of budesonide and formoterol in plasma after a single dose (two inhalations) of the test product and the reference product, with and without charcoal blockade.
  • to assess the safety and tolerability of the test product and the reference product, with and without charcoal blockade.
Read the detailed description

This was a single center, open label, randomized, five-period crossover, single-dose study in healthy volunteers aged 18 to 45 years. A total of 90 volunteers were planned to be enrolled, with 9 subjects in each of the 10 treatment sequences.

The study consisted of 5 treatment periods, each lasting approximately 48h, separated by a washout period of a minimum of 5 days. RS01 and/or Symbicort Turbohaler device use training was provided on Day -1 and Day 1 of each treatment period. Subjects were screened for eligibility to participate in the study -28 to -2 days prior to the first treatment period, and were randomized to one of 10 treatment sequences containing the following 5 treatment arms on Day 1 of the first treatment period:

Treatment A: Z7200 without oral activated charcoal* Treatment B1: Symbicort 1 without oral activated charcoal* Treatment B2: Symbicort 2 without oral activated charcoal* Treatment C: Z7200 with oral activated charcoal** Treatment D: Symbicort with oral activated charcoal**

Subjects were admitted to the clinical unit at 8.00 on the morning of Day -1, and were dosed on the morning of Day 1 following an overnight fast (minimum of 8h). On Day 2, following collection of the 24-h PK blood sample, subjects were discharged.

* Subjects who received treatments A, B1 and B2 rinsed their mouth vigorously with 50 mL water for 3 to 5 sec immediately after the second inhalation.

** A charcoal blockade was used to prevent absorption from oropharyngeal and GI tract, in order to assess the pulmonary deposition of budesonide and formoterol, with periods performed without a charcoal blockade allowing the assessment of the total systemic exposure to the drug.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Male or female 18 to 45 years of age.
  • If female, is currently not pregnant/breast feeding/ or attempting to become pregnant has a negative serum pregnancy test, or is of non- or is of child-bearing potential, willing to commit to using a consistent and acceptable method of or is of child-bearing potential and not sexually active
  • (BMI) of 18.0 to 32.0 kg/m² inclusive and a body weight ≥50 kg.
  • 10 years or more past history of cigarette, \<=5 pack year

Main Exclusion Criteria:

  • in 1 sec (FEV1) value less than 80% of the predicted value and FEV1/FVC (Forced Vital Capacity) ratio \<0.7.
  • History or current evidence of a disease or disorder capable of altering the absorption, metabolism, distribution or elimination of drugs.
  • History or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, haematological, neuropsychological, endocrine, gastrointestinal or pulmonary.
  • Presence of glaucoma, cataracts, ocular herpes simplex, , regardless of the clinical significance or current stability of the disease.
  • positive tests for (HIV), and .
  • Bacterial or viral infection of the upper respiratory tract (including the common cold and flu), sinus, or middle ear within 2 weeks of dosing.
  • Lower respiratory tract infection/pneumonia within the past 3 months.
  • Presence of any disease or condition or regular concomitant treatment (including vitamins and herbal products) known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Screening value of less than 1g/dL above the Lower Limit of Normality
  • History of recurrent vasovagal collapses.
  • History of anaphylactic/anaphylactoid reactions.
  • History of seizures including febrile seizures excluding childhood febrile convulsions.
  • Unable to demonstrate proper inhalation techniques involved in using the delivery devices at screening.
  • Exposure to any drug within 90 days of the Screening Visit.
  • Known or suspected or idiosyncratic reaction to any , any β2 agonist; allergy to milk protein.
  • Use of an inhaled corticosteroid within 30 days or systemic corticosteroid within 60 days of the Screening Visit.
  • Use of medications or herbal medicines that are strong cytochrome P450 3A4 () inhibitors or inducers within 30 days prior to Screening Visit
  • Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study.
  • Use of caffeine containing beverages more than 5 cups/day.
  • Recent or current (suspected) drug abuse or positive result in the drugs abuse test.
  • Recent or current alcohol abuse (regular drinking more than 21 units per week for males and more than 14 units per week for females)
  • Predictable poor compliance, intolerance to charcoal solution, or inability to communicate well with the study centre personnel or inability to participate in all treatment periods.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    A-B1-B2-C-D

    Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 days followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

  • Experimental
    B1-C-A-D-B2

    Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

  • Experimental
    C-D-B1-B2-A

    Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

  • Experimental
    D-B2-C-A-B1

    Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

  • Experimental
    B2-A-D-B1-C

    Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

  • Experimental
    D-C-B2-B1-A

    Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

  • Experimental
    B2-D-A-C-B1

    Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

  • Experimental
    A-B2-B1-D-C

    Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

  • Experimental
    B1-A-C-B2-D

    Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

  • Experimental
    C-B1-D-A-B2

    Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

    Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal

Interventions

  • DrugZ7200 without oral activated charcoal

    Drug pages: Budesonide · Formoterol

    160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).

    Also known as: budesonide/formoterol

  • DrugSymbicort Turbohaler without oral activated charcoal

    Drug pages: Budesonide · Formoterol

    320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2 denote Symbicort without oral activated charcoal administered in two different periods).

    Also known as: budesonide/formoterol

  • DrugZ7200 with oral activated charcoal

    Drug page: Charcoal

    160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).

    Also known as: budesonide/formoterol with coadministration of charcoal

  • DrugSymbicort Turbohaler with oral activated charcoal

    Drug page: Charcoal

    320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).

    Also known as: budesonide/formoterol with coadministration of charcoal

06

What researchers measure

Primary outcomes

  1. AUC0-last of Budesonide With and Without Charcoal Blockade

    Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

  2. AUC0-last of Formoterol With and Without Charcoal Blockade

    Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

  3. Cmax of Budesonide With and Without Charcoal Blockade

    Maximum plasma level of budesonide with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

  4. Cmax of Formoterol With and Without Charcoal Blockade

    Maximum plasma level of formoterol with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

Secondary outcomes

  1. AUC0-30 of Budesonide With and Without Charcoal Blockade.

    Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-30 min (0, 2, 5, 10, 15, 20, and 30 min)

  2. AUC0-30 of Formoterol With and Without Charcoal Blockade.

    Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-30 min (0, 2, 5, 10, 15, 20, and 30 min)

  3. AUC0-∞ of Budesonide With and Without Charcoal Blockade

    Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

  4. AUC0-∞ of Formoterol With and Without Charcoal Blockade

    Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

  5. Tmax for Budesonide With and Without Charcoal Blockade

    Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

  6. Tmax for Formoterol With and Without Charcoal Blockade

    Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

  7. t1/2 for Budesonide With and Without Charcoal Blockade

    Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

  8. t1/2 for Formoterol With and Without Charcoal Blockade

    Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)

  9. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 refers to the volume of air that an individual can exhale during a forced breath in 1 second. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: At 75 min (1.25 hours) post-dose

  10. Change From Baseline in the Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC)

    FVC = Forced vital capacity. It is the full amount of air that can be exhaled with effort in a complete breath. FEV1/FVC = Tiffenau-Pinelli Index. This parameter represents the measurement of the amount of air an individual can forcefully exhale from his/her lungs. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: At 75 min (1.25 hours) post-dose

  11. Change From Baseline in Peak Expiratory Flow Rate (PEFR)

    PEFR is the highest rate at which gases can be expelled from the lungs via an open mouth. Its measurement is a simple procedure in which an individual takes a full inspiration and blows out as forcibly as possible into an instrument called a peak flow meter, which measures the maximal gas flow in an exhalation in liters per minute. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

    Time frame: At 75 min (1.25 hours) post-dose

07

Results

Posted Jan 26, 2022
Limitations and caveats
Limitations and Caveats not specified

Participant flow

Subjects were screened for eligibility -28 to -2 days prior to the first treatment period. On Day -1 of the first treatment period, i.d. before randomization, subjects were trained on both the RS01 and Symbicort Turbohaler devices.

Participant flow — Overall Study
MilestoneA-B1-B2-C-DB1-C-A-D-B2C-D-B1-B2-AD-B2-C-A-B1B2-A-D-B1-CD-C-B2-B1-AB2-D-A-C-B1A-B2-B1-D-CB1-A-C-B2-DC-B1-D-A-B2
Started910999899109
A9899989999
B1910998899109
B29899989999
C9899889899
D9899889999
Completed9899889899
Not completed0200100110
Withdrew: Physician decision0100000000
Withdrew: Adverse event0100000000
Withdrew: Withdrawal by subject0000100100
Withdrew: Lost to follow-up0000000010

Outcome measures

PrimaryAUC0-last of Budesonide With and Without Charcoal Blockade

Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Geometric mean · pg*h/mL
AUC0-last of Budesonide With and Without Charcoal Blockade
pg*h/mLTreatment ATreatment BTreatment CTreatment D
AUC0-last of Budesonide With and Without Charcoal Blockade1710 ± 17.91710 ± 33.11570 ± 20.21530 ± 39.7
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = <0.001 · Adjusted geometric means ratio: 100.64 · 90% CI 95.82 to 105.69
  • Treatment C vs Treatment D · Mixed Models Analysis · p = <0.001 · Adjusted geometric means ratio: 102.11 · 90% CI 95.55 to 109.13
PrimaryAUC0-last of Formoterol With and Without Charcoal Blockade

Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Geometric mean · pg*h/mL
AUC0-last of Formoterol With and Without Charcoal Blockade
pg*h/mLTreatment ATreatment BTreatment CTreatment D
AUC0-last of Formoterol With and Without Charcoal Blockade46.1 ± 22.752.6 ± 37.339.0 ± 25.442.8 ± 50.8
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.002 · Adjusted geometric means ratio: 87.96 · 90% CI 83.31 to 92.86
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.005 · Adjusted geometric means ratio: 91.17 · 90% CI 83.94 to 99.04
PrimaryCmax of Budesonide With and Without Charcoal Blockade

Maximum plasma level of budesonide with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Geometric mean · pg/mL
Cmax of Budesonide With and Without Charcoal Blockade
pg/mLTreatment ATreatment BTreatment CTreatment D
Cmax of Budesonide With and Without Charcoal Blockade1080 ± 69.8686 ± 53.21110 ± 72.8663 ± 50.6
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 1.00 · Adjusted geometric means ratio: 157.86 · 90% CI 144.12 to 172.91
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 1.00 · Adjusted geometric means ratio: 166.81 · 90% CI 148.35 to 187.57
PrimaryCmax of Formoterol With and Without Charcoal Blockade

Maximum plasma level of formoterol with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Geometric mean · pg/mL
Cmax of Formoterol With and Without Charcoal Blockade
pg/mLTreatment ATreatment BTreatment CTreatment D
Cmax of Formoterol With and Without Charcoal Blockade10.1 ± 37.111.9 ± 46.110.3 ± 35.711.7 ± 50.4
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.012 · Adjusted geometric means ratio: 85.22 · 90% CI 79.66 to 91.17
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.020 · Adjusted geometric means ratio: 87.74 · 90% CI 81.48 to 94.47
SecondaryAUC0-30 of Budesonide With and Without Charcoal Blockade.

Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-30 min (0, 2, 5, 10, 15, 20, and 30 min)
Reported as:
Geometric mean · pg*h/mL
AUC0-30 of Budesonide With and Without Charcoal Blockade.
pg*h/mLTreatment ATreatment BTreatment CTreatment D
AUC0-30 of Budesonide With and Without Charcoal Blockade.313 ± 30.5238 ± 48.9315 ± 32.5237 ± 47.5
SecondaryAUC0-30 of Formoterol With and Without Charcoal Blockade.

Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-30 min (0, 2, 5, 10, 15, 20, and 30 min)
Reported as:
Geometric mean · pg*h/mL
AUC0-30 of Formoterol With and Without Charcoal Blockade.
pg*h/mLTreatment ATreatment BTreatment CTreatment D
AUC0-30 of Formoterol With and Without Charcoal Blockade.3.37 ± 30.13.88 ± 42.13.36 ± 29.73.76 ± 47.9
SecondaryAUC0-∞ of Budesonide With and Without Charcoal Blockade

Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Geometric mean · pg*h/mL
AUC0-∞ of Budesonide With and Without Charcoal Blockade
pg*h/mLTreatment ATreatment BTreatment CTreatment D
AUC0-∞ of Budesonide With and Without Charcoal Blockade1820 ± 18.21830 ± 33.01670 ± 20.31640 ± 38.5
SecondaryAUC0-∞ of Formoterol With and Without Charcoal Blockade

Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Geometric mean · pg*h/mL
AUC0-∞ of Formoterol With and Without Charcoal Blockade
pg*h/mLTreatment ATreatment BTreatment CTreatment D
AUC0-∞ of Formoterol With and Without Charcoal Blockade55.4 ± 23.463.0 ± 36.046.8 ± 26.153.7 ± 37.6
SecondaryTmax for Budesonide With and Without Charcoal Blockade

Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Median · hours
Tmax for Budesonide With and Without Charcoal Blockade
hoursTreatment ATreatment BTreatment CTreatment D
Tmax for Budesonide With and Without Charcoal Blockade0.080 (0.03 to 0.51)0.250 (0.03 to 1.00)0.040 (0.03 to 0.75)0.250 (0.03 to 1.00)
SecondaryTmax for Formoterol With and Without Charcoal Blockade

Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Median · hours
Tmax for Formoterol With and Without Charcoal Blockade
hoursTreatment ATreatment BTreatment CTreatment D
Tmax for Formoterol With and Without Charcoal Blockade0.080 (0.04 to 0.25)0.080 (0.03 to 0.33)0.080 (0.08 to 0.25)0.080 (0.08 to 0.51)
Secondaryt1/2 for Budesonide With and Without Charcoal Blockade

Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Geometric mean · hours
t1/2 for Budesonide With and Without Charcoal Blockade
hoursTreatment ATreatment BTreatment CTreatment D
t1/2 for Budesonide With and Without Charcoal Blockade3.21 ± 22.23.14 ± 23.23.23 ± 23.63.01 ± 23.4
Secondaryt1/2 for Formoterol With and Without Charcoal Blockade

Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Reported as:
Geometric mean · hours
t1/2 for Formoterol With and Without Charcoal Blockade
hoursTreatment ATreatment BTreatment CTreatment D
t1/2 for Formoterol With and Without Charcoal Blockade9.35 ± 25.49.28 ± 26.69.45 ± 27.69.08 ± 26.8
SecondaryChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

FEV1 refers to the volume of air that an individual can exhale during a forced breath in 1 second. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
At 75 min (1.25 hours) post-dose
Reported as:
Mean · liters
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
litersTreatment ATreatment BTreatment CTreatment D
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)0.188 ± 0.1670.170 ± 0.1610.173 ± 0.1430.153 ± 0.131
SecondaryChange From Baseline in the Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC)

FVC = Forced vital capacity. It is the full amount of air that can be exhaled with effort in a complete breath. FEV1/FVC = Tiffenau-Pinelli Index. This parameter represents the measurement of the amount of air an individual can forcefully exhale from his/her lungs. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
At 75 min (1.25 hours) post-dose
Reported as:
Mean · Ratio
Change From Baseline in the Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC)
RatioTreatment ATreatment BTreatment CTreatment D
Change From Baseline in the Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC)3.94 ± 3.723.78 ± 2.903.75 ± 2.733.83 ± 2.84
SecondaryChange From Baseline in Peak Expiratory Flow Rate (PEFR)

PEFR is the highest rate at which gases can be expelled from the lungs via an open mouth. Its measurement is a simple procedure in which an individual takes a full inspiration and blows out as forcibly as possible into an instrument called a peak flow meter, which measures the maximal gas flow in an exhalation in liters per minute. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.

Time frame:
At 75 min (1.25 hours) post-dose
Reported as:
Mean · L/min
Change From Baseline in Peak Expiratory Flow Rate (PEFR)
L/minTreatment ATreatment BTreatment CTreatment D
Change From Baseline in Peak Expiratory Flow Rate (PEFR)32.3 ± 42.022.4 ± 38.730.3 ± 34.319.3 ± 39.1

Adverse events

Collected over Throughout the study till the end of trial assessment, that is from the first day of screening up to 6 weeks.. Non-serious events are listed at a 1.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/88 (0%)0/88 (0%)15/88 (17%)
Treatment B0/91 (0%)0/91 (0%)22/91 (24.2%)
Treatment C0/86 (0%)0/86 (0%)13/86 (15.1%)
Treatment D0/87 (0%)0/87 (0%)11/87 (12.6%)
Most frequent other events
Showing 10 of 41
Most frequent other events
EventTreatment ATreatment BTreatment CTreatment D
HeadacheNervous system disorders5/886/916/862/87
DizzinessNervous system disorders2/883/912/861/87
HypoaesthesiaNervous system disorders0/883/910/861/87
coughRespiratory, thoracic and mediastinal disorders0/880/912/860/87
Skin AbrasionInjury, poisoning and procedural complications0/880/910/862/87
EpistaxisRespiratory, thoracic and mediastinal disorders2/881/910/860/87
Vessel puncture site bruiseGeneral disorders2/882/910/861/87
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders0/882/911/861/87
NauseaGastrointestinal disorders1/882/910/860/87
Blood creatine phosphokinase increasedInvestigations0/882/910/860/87

Baseline characteristics

Safety population: All subjects who received at least one dose (2 inhalations) of investigational medicinal product.

Age, Categorical
Age, Categorical(Participants)A-B1-B2-C-DB1-C-A-D-B2C-D-B1-B2-AD-B2-C-A-B1B2-A-D-B1-CD-C-B2-B1-AB2-D-A-C-B1A-B2-B1-D-CB1-A-C-B2-DC-B1-D-A-B2Total
<=18 years00000000000
Between 18 and 65 years91099989910991
>=65 years00000000000
Age, Continuous
Age, Continuous(years)A-B1-B2-C-DB1-C-A-D-B2C-D-B1-B2-AD-B2-C-A-B1B2-A-D-B1-CD-C-B2-B1-AB2-D-A-C-B1A-B2-B1-D-CB1-A-C-B2-DC-B1-D-A-B2Total
Mean28.7 ± 8.129.9 ± 9.032.9 ± 9.430.8 ± 8.323.8 ± 3.826.1 ± 8.525.8 ± 6.931.7 ± 7.730.7 ± 9.726.2 ± 7.228.7 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)A-B1-B2-C-DB1-C-A-D-B2C-D-B1-B2-AD-B2-C-A-B1B2-A-D-B1-CD-C-B2-B1-AB2-D-A-C-B1A-B2-B1-D-CB1-A-C-B2-DC-B1-D-A-B2Total
Female454242133129
Male555756867862
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A-B1-B2-C-DB1-C-A-D-B2C-D-B1-B2-AD-B2-C-A-B1B2-A-D-B1-CD-C-B2-B1-AB2-D-A-C-B1A-B2-B1-D-CB1-A-C-B2-DC-B1-D-A-B2Total
American Indian or Alaska Native00000000000
Asian01001001205
Native Hawaiian or Other Pacific Islander00000000000
Black or African American10002100004
White699867887977
More than one race20010010105
Unknown or Not Reported00000000000
Region of Enrollment
Region of Enrollment(participants)A-B1-B2-C-DB1-C-A-D-B2C-D-B1-B2-AD-B2-C-A-B1B2-A-D-B1-CD-C-B2-B1-AB2-D-A-C-B1A-B2-B1-D-CB1-A-C-B2-DC-B1-D-A-B2Total
United Kingdom91099989910991
08

Study locations

1 site
  • Quotient Clinical Ltd
    Ruddington, NG11 6JS, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2022, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2015
First posted
Dec 16, 2015
Start
Jan 2016
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results first posted
Jan 26, 2022
Last update
Feb 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02631941
Lead sponsor
Zambon SpA
Responsible party
Sponsor
First posted
Dec 16, 2015
Start date
Jan 2016
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Jan 26, 2022
Last update
Feb 23, 2022

Study contacts

Sharan Sidhu, MBChB
principal investigator · Quotient Clinical Limited

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol · Charcoal

Start the discussion